For over two decades, the Multiple Myeloma Program at Washington University has been a leader in research and patient care.
Our team of experienced physicians and healthcare professionals uses advanced diagnostic techniques, such as bone marrow biopsies, imaging studies, and genetic testing, to diagnose multiple myeloma and related diseases. We are actively involved in clinical trials and translational research to advance the understanding of multiple myeloma and discover novel treatment approaches.
Make an Appointment
Referring physicians or patients can call 314-454-8304 to schedule a consultation with one of our Multiple Myeloma Program physicians.
Make a gift to Multiple Myeloma Research
Multiple Myeloma and Related Diseases
Our team focuses on diagnosing and treating of multiple myeloma and related diseases. We perform consultations on over 400 patients per year with a new diagnosis of myeloma and continue to evaluate and treat over 1000 patients with these diseases annually.
The Myeloma Program physicians treat patients with the following diagnoses:
- Multiple myeloma
- Smoldering myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- Light chain amyloidosis
- POEMS syndrome
- Waldenstrom’s macroglobulinemia (Lymphoplasmacytic lymphoma)
- Light chain deposition disease
Our Treatment Approach
Collaboration and teamwork are essential to the Washington University Multiple Myeloma Program. Our physicians work closely with other specialists including radiation oncologists, surgeons, nephrologists, pain specialists, radiologists, pathologists and other supportive care experts to provide comprehensive, well-rounded care. This multidisciplinary approach ensures that patients receive not only the best medical treatment but also the necessary support for managing the physical and emotional challenges associated with multiple myeloma.
Patients have an initial consultation with one of our team to confirm a diagnosis and perform necessary studies for accurate staging. All new patients are discussed with the myeloma and BMT physicians to develop a personalized treatment and determine the most appropriate therapies for each individual. Many patients are eligible for clinical trials of new drugs or new drug combinations and your physician will discuss these options with you. Treatment options that we offer include:
- Blood and Marrow Transplantation
- CAR-T Cell Therapy
- Radiation Therapy
- Clinical Trials
Ravi Vij, MD, MBA
Dr. Vij is the Director of the Multiple Myeloma Program. His research is focused on employing novel therapeutics including CAR-T therapy and bispecifics to improve outcomes of patients with cancer. He also works closely with laboratory scientists involved in using state of the art technology to study the genomics of cancer and the immune-microenvironment.
Mark A. Schroeder, MD
Dr. Schroeder provides care for newly diagnosed and relapsed myeloma patients. He is an expert in hematopoietic cell transplant and immunotherapies for myeloma such as CART and bispecific antibodies. His clinical research interest includes post-transplant maintenance approaches and novel therapies for high-risk myeloma.
Michael J. Slade, MD, MSCI
Dr. Slade specializes in the clinical care of patients with multiple myeloma and related plasma cell disorders, with a focus on bone marrow transplant and cellular immunotherapy. His research interests include improving response to immunotherapy for multiple myeloma and customizing cancer treatment based on sensitive markers of myeloma remission.
Keith E. Stockerl-Goldstein, MD
Dr. Stockerl-Goldstein treats patients with multiple myeloma, light chain amyloidosis and related diseases. His research is focused on therapies for multiple myeloma and amyloidosis including stem cell transplantation and immunotherapies. He serves as Co-Director for the Washington University Amyloid Center of Excellence
- Maggie Kavanaugh
- Jordan Smith
- Angela Vickroy
- Kari Wilson
- Jason Clark
- Monica Frasier
- Lindsay Hobbs
- MaryKate Horn
- Abbie Johnessee
- Rebecca Thompson
- Jarrod Williams
Research and Clinical Trials
Research and innovation are fundamental pillars of the Multiple Myeloma Program. The team at Washington University is actively engaged in conducting clinical trials as well as basic and translational research to advance the understanding of multiple myeloma and discover novel treatment approaches. Their contributions have led to significant advancements in the field and have helped shape the current standards of care for multiple myeloma patients worldwide. In fact, virtually all therapies to treat myeloma approved by the FDA since 2003 were available in clinical trials at Washington University prior to their approval.
Ongoing Clinical Trial Highlights
- Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Randomized trial of lenalidomide plus daratumumab versus lenalidomide for patients with high-risk untreated smoldering multiple myeloma
- Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies
Ongoing clinical research tissue bank study evaluating the usefulness of molecular profiling of myeloma cells to understand treatment response and prognosis
- A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 Versus Placebo in Patients With Mayo Stage IIIb AL Amyloidosis
Randomized clinical trial of the anti-amyloid antibody CAEL-101 versus placebo in patients with untreated advanced-stage light chain amyloidosis